| Title |
Early Direct and Indirect Impact of Quadrivalent HPV (4HPV) Vaccine on Genital Warts: a Systematic Review
|
|---|---|
| Published in |
Advances in Therapy, January 2015
|
| DOI | 10.1007/s12325-015-0178-4 |
| Pubmed ID | |
| Authors |
Luciano Mariani, Patrizia Vici, Barbara Suligoi, Giovanni Checcucci-Lisi, Rosybel Drury |
| Abstract |
Since 2007, many countries have implemented national human papillomavirus (HPV) vaccination programs with the quadrivalent HPV (4HPV) vaccine that has been shown to be efficacious in clinical trials involving 25,000 subjects. Two vaccine serotypes, HPV16 and 18, are responsible for cervical cancer and other HPV-related cancers, but the impact of the 4HPV vaccine on these cancers cannot be seen immediately as there is a considerable lag between infection with HPV and cancer development. The other two serotypes, HPV6 and 11, are responsible for genital warts (GWs), which develop within a few months after infection, making GWs an early clinical endpoint for the assessment of the impact of 4HPV vaccination. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 115 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Argentina | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 112 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 19 | 17% |
| Student > Ph. D. Student | 13 | 11% |
| Researcher | 9 | 8% |
| Student > Bachelor | 7 | 6% |
| Student > Postgraduate | 6 | 5% |
| Other | 26 | 23% |
| Unknown | 35 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 36% |
| Agricultural and Biological Sciences | 7 | 6% |
| Social Sciences | 5 | 4% |
| Nursing and Health Professions | 5 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 12 | 10% |
| Unknown | 41 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2023.
All research outputs
#2,480,531
of 23,577,654 outputs
Outputs from Advances in Therapy
#205
of 2,410 outputs
Outputs of similar age
#36,689
of 356,369 outputs
Outputs of similar age from Advances in Therapy
#2
of 17 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,410 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,369 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.